Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 13/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 12/20 | 0.37 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186605 | 0.78 | KDM4E (0.47) | CYP11B2KDM4EALDH1A1POLB | |
| SCHEMBL29929823 | 0.78 | EGLN2 (0.42) | EGLN2CYP11B2KDM4EALDH1A1POLB | |
| SCHEMBL186339 | 0.78 | EGLN2 (0.42) | EGLN2CYP11B2KDM4EALDH1A1POLB | |
| SCHEMBL34470891 | 0.78 | ALDH1A1 (0.50) | EGLN2CYP11B2KDM4EALDH1A1CYP11B1 | |
| SCHEMBL12099239 | 0.77 | ALDH1A1 (0.41) | CYP11B2KDM4EALDH1A1POLBCYP11B1 | |
| SCHEMBL4586295 | 0.75 | KDM4E (0.40) | KDM4EALDH1A1POLBS1PR3S1PR1 | |
| SCHEMBL11155546 | 0.75 | KDM4E (0.40) | CYP11B2KDM4EALDH1A1POLBCYP11B1 | |
| SCHEMBL1973193 | 0.75 | ALDH1A1 (0.40) | KDM4EALDH1A1POLB | |
| SCHEMBL12838156 | 0.75 | KDM4E (0.40) | CYP11B2KDM4EALDH1A1POLBCYP11B1 | |
| SCHEMBL125638 | 0.75 | PIK3CD (0.51) | KDM4EALDH1A1POLBKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12441754-B2 | Galactoside inhibitor of galectins | GALECTO BIOTECH AB (DK) | 2025-10-14 | — | — | US | disclosed |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2025-05-01 | — | — | US | disclosed |
| CN-119504705-A | Non-peptide somatostatin 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| CN-114585614-B | Non-peptide somatostatin 5 receptor agonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-12-03 | — | — | CN | disclosed |
| CN-117843565-A | Preparation method and application of pyridine compound | 南京正荣医药化学有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230014870-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | GALECTO BIOTECH AB (DK) | 2023-01-19 | — | — | US | disclosed |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| CN-110885319-B | Sulfonamide compounds as sodium channel blockers and uses thereof | 成都康弘药业集团股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-110885328-B | Sulfonamide compounds as sodium channel blockers and uses thereof | 成都康弘药业集团股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED | 2009-10-08 | — | — | US | disclosed |
| WO-2009099594-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2008121333-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121333-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2008-10-02 | — | — | US | disclosed |
| US-6204221-B1 | Herbicides | SYNGENTA CROP PROTECTION, INC. | 2001-03-20 | — | — | US | disclosed |
| EP-0941222-A2 | PYRAZOLE DERIVATIVES USEFUL AS HERBICIDES | Novartis AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| WO-1998021199-A2 | PYRAZOLE DERIVATIVES USEFUL AS HERBICIDES | NOVARTIS AG (CH) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, SSTR3 | EGLN2 679/4885CYP11B2 1224/4885KDM4E 4514/4885 |
| US-20230014870-A1 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | LGALS1, LGALS3, LGALS2 | EGLN2 2977/4885CYP11B2 423/4885KDM4E 3905/4885 |
| US-20090253737-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | TNNC1, TNNI3, TNNT2 | EGLN2 3763/4885CYP11B2 1757/4885KDM4E 4841/4885 |
| US-20080242695-A1 | Certain Chemical Entities, Compositions, and Methods | TNNC1, TNNI3, TNNT2 | EGLN2 4220/4885CYP11B2 2387/4885KDM4E 4360/4885 |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | EGLN2 679/4885CYP11B2 1224/4885KDM4E 4514/4885 |
| US-12441754-B2 | Galactoside inhibitor of galectins | LGALS1, LGALS3, LGALS2 | EGLN2 2859/4885CYP11B2 471/4885KDM4E 3880/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | EGLN2 1178/4885CYP11B2 1699/4885KDM4E 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.